AKAkihiro Kanematsu

Akihiro Kanematsu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akihiro Kanematsu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • H. Haga

    Laboratory of Diagnostic Pathology, Kyoto University Hospital, Sakyo‐ku, Kyoto, Japan

    1 shared publication
  • K. Yoshimura

    Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    1 shared publication
  • Kazuyoshi Johnin

    Department of Urology, Kyoto University, Kyoto, JapanUrology Clinic, Shiga Medical Center for Children, Moriyama, JapanDepartment of Urology, Shiga University of Medical Sciences, Otsu, Japan

    1 shared publication
  • Koji Yoshimura

    Department of Urology, Kyoto University, Kyoto, JapanUrology Clinic, Shiga Medical Center for Children, Moriyama, JapanDepartment of Urology, Shiga University of Medical Sciences, Otsu, Japan

    1 shared publication
  • Masaaki Imamura

    Department of Urology, Kyoto University, Kyoto, JapanUrology Clinic, Shiga Medical Center for Children, Moriyama, JapanDepartment of Urology, Shiga University of Medical Sciences, Otsu, Japan

    1 shared publication
  • N. Yoshimura

    Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

    1 shared publication

Latest Publications

  • Open Access

    Comparison of the Effects by Obybutynin and Tolterodine on Spina Bifida Patients: A Pilot Crossover Study

    by Akihiro Kanematsu, Kazuyoshi Johnin, Koji Yoshimura, Masaaki Imamura, Osamu Ogawa

    To compare the effects of obybutynin and tolterodine in neurogenic bladder patients with spina bifida in a crossover study. Seven myelomeningocele and one spinal lipoma cases, maintained with obybutynin and clean intermittent catheterization for more than 60 months, were enrolled. Age ranged from 8 to 23 years (mean 12.0, male/ female = 2/6). After 2 weeks of washout period, obybutynin (0.3 mg/kg, maximum 12 mg) or tolterodine (0.12 mg/kg, maximum 4 mg) was administered for 4 weeks, and then switched to the other drug for 4 weeks. At the end of the three periods, the patients and/or parents documented urinary storage status and adverse effects, and urodynamic study was performed. In seven cases undergoing sequential urodynamic study, the baseline compliance of the patients (6.81 ± 1.83) increased to 9.98 ± 4.97 by obybutynin and 10.16 ± 2.53 by tolterodine (P < 0.05 for each). Better compliance was noted in two cases with tolterodine and in two cases with obybutynin. Stronger adverse effects were reported in three out of eight patients (37.5%) by obybutynin and three out of eight patients (37.5%) by tolterodine. Although storage effect and side effects were equivalent for total patients, markedly diverse response was noted for each patient, with five choosing tolterodine and three choosing obybutynin. Individualized evaluation is required for optimal choice of anticholinergics.


  • Voided stain on paper method for analysis of mouse urination

    by Y. Sugino, A. Kanematsu, Y. Hayashi, H. Haga, N. Yoshimura, K. Yoshimura, O. Ogawa

    Aims: To evaluate the usefulness of a quantification method using filter paper for analyzing minute voided urine of the mouse.Methods: Voided stain on paper (VSOP) method; the correlation between area of stained spot on a filter paper and amount of applied liquid was calculated. Voiding behavior of the mice was analyzed by placing the animal above the same filter paper and recording voided time and area over 2 hr. The usefulness of the VSOP method was tested in analysis of the voiding behavior of five female 7‐week‐old ddY mice treated with cyclophosphamide (CPM, 150 mg/kg, intraperitoneally) and five control ones, in comparison with the histology of CPM‐induced cystitis. Further, the voided volume of male and female ddY mouse ranging from 2 to 13 weeks was assessed.Results: There was a linear correlation between liquid volume and stained area on the filter paper (y = 16.472x − 22.411, R2 = 0.9981). Between control mice and those with histologically proven CPM cystitis, there was a significant difference in voided volume (362.7 ± 51.9 and 127.8 ± 100.0 µl, < 0.001) and voiding interval (10.30 ± 3.10 and 4.47 ± 1.70 min, < 0.001). Voided volume of ddY mice was quantifiable from as early as 2‐week old, increased along with their growth and correlated well with their body weight [(voided volume: µl) = 10.8 × (body weight: g) + 32, R2 = 0.762].Conclusions: The VSOP method is a useful tool for evaluating voiding behavior of the mouse, including those with small bladder capacity. Neurourol. Urodynam. 27:548–552, 2008.